Key result
Activation of the counterbalancing ACE2−Ang-(1–7)−Mas pathway demonstrated efficacy in preclinical models of pulmonary hypertension, paving the way for future clinical trials.
Answers are grounded in this paper and cite their sources.
Encouraging clinical proof-of-concept supports further large clinical trials of ACE2 pathway stimulation for pulmonary arterial hypertension.
Since its initial discovery 120 years ago, the understanding of the renin−angiotensin system (RAS) has advanced considerably. In recent years, the identification of new enzymes, peptides and receptors that are constituents of novel identified counterbalancing RAS pathways acting beyond the classical ACE (angiotensin-converting enzyme)/angiotensin (Ang)II/AT1 receptor axis have heralded a new era highlighting its importance in health and disease (figure 1). As a result, it is now well established that inhibition of the classical RAS and activation of the counterbalancing axes (alternative RAS), namely the ACE2−Ang-(1–7)−Mas receptor cascade and the AT2 signalling pathway are two feasible strategies demonstrating efficacies in various cardiovascular and pulmonary disease models, including in various preclinical models of pulmonary hypertension (PH) [1–6]. Based on this highly encouraging clinical proof-of-concept, there is now a clear plan to explore interventions that stimulate the ACE2–Ang-(1–7)–Mas pathway further in large clinical trials http://ow.ly/adXT30k1Z5h
No takes yet. Share an insight, caveat, or question.
Guignabert et al. (2018) conducted an editorial in Pulmonary arterial hypertension. Activation of the ACE2−Ang-(1–7)−Mas pathway was evaluated. Activation of the counterbalancing ACE2−Ang-(1–7)−Mas pathway demonstrated efficacy in preclinical models of pulmonary hypertension, paving the way for future clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: